References
-
1.
Toffoli EC, Sheikhi A, Hoppner YD, de Kok P, Yazdanpanah-Samani M, Spanholtz J, et al. Natural Killer Cells and Anti-Cancer Therapies: Reciprocal Effects on Immune Function and Therapeutic Response. Cancers (Basel). 2021;13(4). [PubMed ID: 33572396]. [PubMed Central ID: PMC7916216]. https://doi.org/10.3390/cancers13040711.
-
2.
Yoon MS, Pham CT, Phan MT, Shin DJ, Jang YY, Park MH, et al. Irradiation of breast cancer cells enhances CXCL16 ligand expression and induces the migration of natural killer cells expressing the CXCR6 receptor. Cytotherapy. 2016;18(12):1532-42. [PubMed ID: 27720639]. https://doi.org/10.1016/j.jcyt.2016.08.006.
-
3.
Baeuerle PA, Reinhardt C. Bispecific T-cell engaging antibodies for cancer therapy. Cancer Res. 2009;69(12):4941-4. [PubMed ID: 19509221]. https://doi.org/10.1158/0008-5472.CAN-09-0547.
-
4.
Tian Z, Liu M, Zhang Y, Wang X. Bispecific T cell engagers: an emerging therapy for management of hematologic malignancies. J Hematol Oncol. 2021;14(1):75. [PubMed ID: 33941237]. [PubMed Central ID: PMC8091790]. https://doi.org/10.1186/s13045-021-01084-4.
-
5.
Ahmad ZA, Yeap SK, Ali AM, Ho WY, Alitheen NB, Hamid M. scFv antibody: principles and clinical application. Clin Dev Immunol. 2012;2012:980250. [PubMed ID: 22474489]. [PubMed Central ID: PMC3312285]. https://doi.org/10.1155/2012/980250.
-
6.
Safarzadeh Kozani P, Safarzadeh Kozani P, Rahbarizadeh F. Novel antigens of CAR T cell therapy: New roads; old destination. Transl Oncol. 2021;14(7):101079. [PubMed ID: 33862524]. [PubMed Central ID: PMC8065293]. https://doi.org/10.1016/j.tranon.2021.101079.
-
7.
Safarzadeh Kozani P, Safarzadeh Kozani P, O'Connor RS. In Like a Lamb; Out Like a Lion: Marching CAR T Cells Toward Enhanced Efficacy in B-ALL. Mol Cancer Ther. 2021;20(7):1223-33. [PubMed ID: 33903140]. [PubMed Central ID: PMC8285067]. https://doi.org/10.1158/1535-7163.MCT-20-1089.
-
8.
Bever CS, Dong JX, Vasylieva N, Barnych B, Cui Y, Xu ZL, et al. VHH antibodies: emerging reagents for the analysis of environmental chemicals. Anal Bioanal Chem. 2016;408(22):5985-6002. [PubMed ID: 27209591]. [PubMed Central ID: PMC4983233]. https://doi.org/10.1007/s00216-016-9585-x.
-
9.
Sheikhi A, Hojjat-Farsangi M. An immunotherapeutic method for COVID-19 patients: a soluble ACE2-Anti-CD16 VHH to block SARS-CoV-2 Spike protein. Hum Vaccin Immunother. 2021;17(1):92-7. [PubMed ID: 32663051]. [PubMed Central ID: PMC7872019]. https://doi.org/10.1080/21645515.2020.1787066.